Join experts Krish Patel, MD, specializing in mantle cell lymphoma treatment, Marek Trněný, MD, PhD, a key contributor to BTK inhibitor trials, and Michael Wang, MD, who offers insights on therapeutic sequencing. They delve into groundbreaking trials like ECHO and SHINE, discussing the role of BTK inhibitors and their effectiveness for older patients. Notably, they address optimal sequencing methods to prevent cross-resistance and strategies for managing cardiac toxicities. Their collaboration underscores a comprehensive approach to enhancing patient care.

Dr. Krish Patel from the Swedish Cancer Institute discusses novel therapies for DLBCL, focusing on bispecific antibody gilteritinib. They compare bispecifics to CAR T-cell therapy, explore fixed duration therapy, step-up dosing, and sequencing therapy for optimal results.